The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Selective Angiotensin II Receptor Antagonism Reduces Insulin Resistance in Obese Zucker Rats
Open accessAbstract
Effects of oral administration of the angiotensin II receptor antagonist (selective AT 1-subtype) irbesartan on glucose tolerance and insulin action on skeletal-muscle glucose transport were assessed in the insulin-resistant obese Zucker rat. In the acute study, obese rats received either vehicle (water) or irbesartan 1 hour before the experiment. Although irbesartan had no effect on glucose transport (2-deoxyglucose uptake) in the epitrochlearis muscle, which consists mainly of type IIb fibers, acute angiotensin II receptor antagonism led to a dose-dependent increase in insulin action in the predominantly type I soleus muscle. Irbesartan at 25 and 50 mg/kg induced significant increases (41% and 50%, respectively;P<0.05) in insulin-mediated glucose transport. Moreover, these acute irbesartan-induced improvements in soleus-muscle glucose transport were associated with enhancements in whole-body insulin sensitivity (r=−0.732;P<0.05), as assessed during an oral glucose tolerance test. After chronic administration of irbesartan (21 days at 50 mg · kg−1· d−1), glucose tolerance was enhanced further, and insulin-mediated glucose transport was significantly elevated in both epitrochlearis (32%) and soleus (73%) muscle. Chronic angiotensin II receptor antagonism was associated with significant increases in glucose transporter-4 (GLUT-4) protein expression in soleus (22%) and plantaris (20%) muscle and myocardium (15%). Chronic irbesartan-induced increases in whole-body insulin sensitivity were associated with increased insulin-mediated glucose transport in both epitrochlearis (r=−0.677;P<0.05) and soleus (r=−0.892;P<0.05) muscle. In summary, angiotensin II receptor (AT 1-subtype) antagonism, either acutely or chronically, improves glucose tolerance, at least in part because of an enhancement in skeletal-muscle glucose transport, and the effect of chronic angiotensin II receptor antagonism on type I skeletal-muscle glucose uptake is associated with an increase in GLUT-4 protein expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeFronzo, R. A., & Ferrannini, E. (1991) · Diabetes Care · doi:10.2337/diacare.14.3.173 · Cited by 4,535
Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM
Boden, G. (1997) · Diabetes · doi:10.2337/diab.46.1.3 · Cited by 1,728
HINDLIMB MUSCLE FIBER POPULATIONS OF FIVE MAMMALS
ARIANO, M. A., EDGERTON, V. R., & ARMSTRONG, R. B. (1973) · Journal of Histochemistry & Cytochemistry · doi:10.1177/21.1.51 · Cited by 1,129
Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases
Kim, S., & Iwao, H. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01434-0 · Cited by 983
Angiotensin II receptor antagonists
Burnier, M., & Brunner, H. (2000) · The Lancet · doi:10.1016/s0140-6736(99)10365-9 · Cited by 707
Glucose transporter protein content and glucose transport capacity in rat skeletal muscles
Henriksen, E. J., Bourey, R. E., Rodnick, K. J., Koranyi, L., Permutt, M. A., & Holloszy, J. O. (1990) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1990.259.4.e593 · Cited by 434
Self-citationClinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension
Israili, Z. (2000) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000991 · Cited by 318
Insulin responsiveness in skeletal muscle is determined by glucose transporter (Glut4) protein level
Kern, M., Wells, J. A., Stephens, J. M., Elton, C. W., Friedman, J. E., Tapscott, E. B., Pekala, P. H., & Dohm, G. L. (1990) · Biochemical Journal · doi:10.1042/bj2700397 · Cited by 267
Exercise training, glucose transporters, and glucose transport in rat skeletal muscles
Rodnick, K. J., Henriksen, E. J., James, D. E., & Holloszy, J. O. (1992) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1992.262.1.c9 · Cited by 185
Self-citationUehara, M., Kishikawa, H., Isami, S., Kisanuki, K., Ohkubo, Y., Miyamura, N., Miyata, T., Yano, T., & Shichiri, M. (1994) · Diabetologia · doi:10.1007/bf00398058 · Cited by 141
Cited by
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Mehta, P. K., & Griendling, K. K. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00287.2006 · Cited by 1,924
Oxidative stress and the etiology of insulin resistance and type 2 diabetes
Henriksen, E. J., Diamond-Stanic, M. K., & Marchionne, E. M. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.12.005 · Cited by 600
Self-citationEmerging role of adipose tissue hypoxia in obesity and insulin resistance
Ye, J. (2009) · International Journal of Obesity · doi:10.1038/ijo.2008.229 · Cited by 543
Masuzaki, H., Yamamoto, H., Kenyon, C. J., Elmquist, J. K., Morton, N. M., Paterson, J. M., Shinyama, H., Sharp, M. G. F., Fleming, S., Mullins, J. J., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17845 · Cited by 434
The metabolic syndrome: role of skeletal muscle metabolism.
Stump, C. S., Henriksen, E. J., Wei, Y., & Sowers, J. R. (2006) · Annals of Medicine · doi:10.1080/07853890600888413 · Cited by 362
Self-citation
Metadata
- Authors
- Henriksen, E. J., Jacob, S., Kinnick, T. R., Teachey, M. K., & Krekler, M.
- Venue
- Hypertension
- Published
- 2001-10
- Volume
- 38
- Issue
- 4
- Pages
- 884-890
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2156783035
- Cited by
- 293
- References
- 32
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective Angiotensin II Receptor Antagonism Reduces Insulin Resistance in Obese Zucker Rats. https://app.cochat.ai/papers/10.1161/hy1101.092970
- The paper
- Henriksen, E. J., Jacob, S., Kinnick, T. R., Teachey, M. K., & Krekler, M. (2001). Selective Angiotensin II Receptor Antagonism Reduces Insulin Resistance in Obese Zucker Rats. Hypertension. https://doi.org/10.1161/hy1101.092970
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.